l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson’s Disease

l-3,4-Dihydroxyphenylalanine (l-DOPA) is the most effective therapeutic agent for Parkinson’s disease (PD). l-DOPA is traditionally believed to be an inert amino acid that exerts actions and effectiveness in PD through its conversion to dopamine. In contrast to this generally accepted idea, l-DOPA i...

Descripción completa

Detalles Bibliográficos
Autores principales: Goshima, Yoshio, Masukawa, Daiki, Kasahara, Yuka, Hashimoto, Tatsuo, Aladeokin, Aderemi Caleb
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785630/
https://www.ncbi.nlm.nih.gov/pubmed/31632270
http://dx.doi.org/10.3389/fphar.2019.01119
_version_ 1783457929315221504
author Goshima, Yoshio
Masukawa, Daiki
Kasahara, Yuka
Hashimoto, Tatsuo
Aladeokin, Aderemi Caleb
author_facet Goshima, Yoshio
Masukawa, Daiki
Kasahara, Yuka
Hashimoto, Tatsuo
Aladeokin, Aderemi Caleb
author_sort Goshima, Yoshio
collection PubMed
description l-3,4-Dihydroxyphenylalanine (l-DOPA) is the most effective therapeutic agent for Parkinson’s disease (PD). l-DOPA is traditionally believed to be an inert amino acid that exerts actions and effectiveness in PD through its conversion to dopamine. In contrast to this generally accepted idea, l-DOPA is proposed to be a neurotransmitter. Recently, GPR143 (OA1), the gene product of ocular albinism 1 was identified as a receptor candidate for l-DOPA. GPR143 is widely expressed in the central and peripheral nervous system. GPR143 immunoreactivity was colocalized with phosphorylated α-synuclein in Lewy bodies in PD brains. GPR143 may contribute to the therapeutic effectiveness of l-DOPA and might be related to pathogenesis of PD.
format Online
Article
Text
id pubmed-6785630
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-67856302019-10-18 l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson’s Disease Goshima, Yoshio Masukawa, Daiki Kasahara, Yuka Hashimoto, Tatsuo Aladeokin, Aderemi Caleb Front Pharmacol Pharmacology l-3,4-Dihydroxyphenylalanine (l-DOPA) is the most effective therapeutic agent for Parkinson’s disease (PD). l-DOPA is traditionally believed to be an inert amino acid that exerts actions and effectiveness in PD through its conversion to dopamine. In contrast to this generally accepted idea, l-DOPA is proposed to be a neurotransmitter. Recently, GPR143 (OA1), the gene product of ocular albinism 1 was identified as a receptor candidate for l-DOPA. GPR143 is widely expressed in the central and peripheral nervous system. GPR143 immunoreactivity was colocalized with phosphorylated α-synuclein in Lewy bodies in PD brains. GPR143 may contribute to the therapeutic effectiveness of l-DOPA and might be related to pathogenesis of PD. Frontiers Media S.A. 2019-10-03 /pmc/articles/PMC6785630/ /pubmed/31632270 http://dx.doi.org/10.3389/fphar.2019.01119 Text en Copyright © 2019 Goshima, Masukawa, Kasahara, Hashimoto and Aladeokin http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Goshima, Yoshio
Masukawa, Daiki
Kasahara, Yuka
Hashimoto, Tatsuo
Aladeokin, Aderemi Caleb
l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson’s Disease
title l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson’s Disease
title_full l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson’s Disease
title_fullStr l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson’s Disease
title_full_unstemmed l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson’s Disease
title_short l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson’s Disease
title_sort l-dopa and its receptor gpr143: implications for pathogenesis and therapy in parkinson’s disease
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785630/
https://www.ncbi.nlm.nih.gov/pubmed/31632270
http://dx.doi.org/10.3389/fphar.2019.01119
work_keys_str_mv AT goshimayoshio ldopaanditsreceptorgpr143implicationsforpathogenesisandtherapyinparkinsonsdisease
AT masukawadaiki ldopaanditsreceptorgpr143implicationsforpathogenesisandtherapyinparkinsonsdisease
AT kasaharayuka ldopaanditsreceptorgpr143implicationsforpathogenesisandtherapyinparkinsonsdisease
AT hashimototatsuo ldopaanditsreceptorgpr143implicationsforpathogenesisandtherapyinparkinsonsdisease
AT aladeokinaderemicaleb ldopaanditsreceptorgpr143implicationsforpathogenesisandtherapyinparkinsonsdisease

Ejemplares similares